Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery

Neuroscience and Biobehavioral Reviews

Volumn 25, Issue 7-8, 2001, Pages 619-626

  Griebel, Guy ^a   Moindrot, Nicolas ^a   Aliaga, Carmen ^a   Simiand, Jacques ^a   Soubrié, Philippe ^a  

^a SANOFI   (France)

Author keywords

Anxiety; Benzodiazepines; Defensive behaviors; Mice; Neurokinin 2 receptor; Neuropeptide antagonists; Neurotensin; Stress

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PHENYL 4 PIPERIDINYL] 1,1 DIMETHYLUREA; ALPRAZOLAM; ANXIOLYTIC AGENT; BEFLOXATONE; BUSPIRONE; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROTENSIN RECEPTOR; PHENELZINE; SAREDUTANT; TRIAZOLAM; UNCLASSIFIED DRUG;

ADAPTIVE BEHAVIOR; ANIMAL BEHAVIOR; ANXIETY NEUROSIS; ARTICLE; DEFENSIVE BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSYCHOLOGIC TEST; RISK ASSESSMENT; STRESS; THREAT; TRANQUILIZING ACTIVITY;

EID: 0035712323     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(01)00045-8     Document Type: Short Survey

References (55)

1. Animal models for the study of anti-anxiety agents: A review
2. Ethologically-based animal models of anxiety disorders
3. Animal models of anxiety: Where next?
4. Affect and aggression: An animal model applied to human behavior
5. Defensive behavior of laboratory and wild Rattus norvegicus
6. A model of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities
7. Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: A factor analytic study
8. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives
9. Review of current treatment in panic disorder
10. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
11. Buspirone: Future directions
12. Serotonergic drugs in animal models of anxiety: An update
13. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
14. Nonpeptide antagonists of neuropeptide receptors: Tools for research and therapy
15. Receptors and antagonists for substance P and related peptides
16. Neurotransmitter functions of mammalian tachykinins
17. The mammalian tachykinin receptors
18. Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat
19. Astroglial distribution of neurokinin-2 receptor immunoreactivity in the rat spinal cord
20. 3H]acetylcholine release in mouse striatum through multiple receptor subtypes
21. Recent advances in neurokinin receptor antagonists
22. 1 antagonist SR 140333 in the mouse black and white box model
23. Behavioral effects of intracerebroventricular injection of selective tachykinin agonists and antagonists
24. 2 receptor antagonist, in rodent and primate models of anxiety
25. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice
26. 2 receptor antagonist, releases suppressed behaviours in a novel aversive environment
27. 2 receptor antagonist on emotional processes in rodents
28. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami
29. Neurotensin, a multi-action peptide hormone
30. Interactions of neurotensin with brain dopamine systems: Biochemical and behavioral studies
31. The effects of neurotensin on anterior pituitary hormone secretion
32. Neurotensin: Distribution of hypothermic response in mammalian and submammalian vertebrates
33. Physiological mechanisms of the analgesic effect of neurotensin
34. Distribution of neuropeptides in the limbic system of the rat: The amygdaloid complex
35. Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat
36. Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists
37. Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus
38. Stimulation of CRH-mediated ACTH secretion by central administration of neurotensin: Evidence for the participation of the paraventricular nucleus
39. The effect of stressor controllability on stress-induced neuropeptide mRNA expression within the paraventricular nucleus of the hypothalamus
40. Cold water swim stress increases the expression of neurotensin mRNA in the lateral hypothalamus and medial preoptic regions of the rat brain
41. Structure and functional expression of the cloned rat neurotensin receptor
42. Molecular cloning of a levocabastine-sensitive neurotensin binding site
43. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain
44. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor
45. Localization of neuropeptide receptor mRNA in rat brain: Initial observations using probes for neurotensin and substance P receptors
46. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain
47. Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain
48. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor
49. Turning behavior induced by intrastriatal injection of neurotensin in mice: Sensitivity to non-peptide neurotensin antagonists
50. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission
51. Central administration of the neurotensin receptor antagonist, SR48892, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity
52. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries
53. 2 receptor antagonist, SR48968 on the CRF-induced activation of the NE locus coeruleus-prefrontal cortex system of the rat
54. Characterization of the behavioral profile of the non peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents - Comparison with diazepam and buspirone
55. The mouse defense test battery: An experimental model of different emotional states